Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Ro
Cancer Res Treat. 2019;51(1):43-52. Published online 2018 Feb 14 DOI: https://doi.org/10.4143/crt.2017.562
Citations to this article as recorded by 
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
Jasgit C. Sachdev, Pamela Munster, Donald W. Northfelt, Hyo Sook Han, Cynthia Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey Anders
Breast Cancer Research and Treatment.2021; 185(3): 759. CrossRef
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar D. Sardesai, Kevin Kalinsky, Amelia B. Zelnak, Robert Weaver, Tiffany Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab,
New England Journal of Medicine.2021; 384(16): 1529. CrossRef
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
Jennifer A. Weiss, Andrew Nicklawsky, Jodi A. Kagihara, Dexiang Gao, Christine Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, Sarah L. Davis, Stephen Leong, Sue Gail Eckhardt, Jennifer R. Diamond
Cancer Medicine.2020; 9(23): 8801. CrossRef
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
Vito Lorusso, Agnese Latorre, Francesco Giotta, Ozkan Kanat
Journal of Oncology.2020; 2020: 1. CrossRef
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita C. Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan
New England Journal of Medicine.2019; 380(8): 741. CrossRef
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
I. Kümler, R. L. Eefsen, Peter Grundtvig Sørensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen
Cancer Chemotherapy and Pharmacology.2019; 84(2): 441. CrossRef
Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy
Burak Yasin Aktas, Gurkan Guner, Deniz Can Guven, Cagatay Arslan, Omer Dizdar
Expert Review of Anticancer Therapy.2019; 19(7): 589. CrossRef
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
Jennifer Weiss, Ashley Glode, Wells A. Messersmith, Jennifer Diamond
Expert Review of Anticancer Therapy.2019; 19(8): 673. CrossRef